Pharmaceutical intermediates
Vibegron Intermediates
6 pharmaceutical intermediates for Vibegron. Indication: Overactive Bladder; Urinary Incontinence.
About Vibegron
- Originator
- Merck & Co Inc; Roivant Sciences Inc
- Indication
- Overactive Bladder; Urinary Incontinence
- Approved Date
- 12/23/2020
- NCE Patent
- 12/23/2025
- DS/DP
- 04/02/2029
Available intermediates
6 intermediates currently listed for Vibegron. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMidine-6-carboxylic acid | 1190392-22-3 | / | / |
| tert-butyl(4-(3-(dimethoxyphosphoryl)-2-oxopropyl)phenyl)carbamate | 494224-44-1 | / | / |
| (1R,2R)-2-amino-6-(4-nitrophenyl)-1-phenylhex-5-yn-1-olhydrochloride | 1628836-08-7 | / | / |
| (R)-((2R,5S)-5-(4-aminobenzyl)pyrrolidin-2-yl)(phenyl)methanol | 1295539-30-8 | / | / |
| tert-butyl(4R,5R)-4-(hydroxymethyl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate | 1009092-91-4 | / | / |
| tert-butyl(4R,5R)-4-((E)-4-(4-((tert-butoxycarbonyl)amino)phenyl)-3-oxobut-1-en-1-yl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate | 1426235-01-9 | / | / |
Building toward Vibegron?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →